✦ LIBER ✦

29 The use of erlotinib as second line treatment in patients with non-small cell lung carcinoma (NSCLC) in Birmingham. Does EGFR play a role?

✍ Scribed by Reeve, N.; Cook, M.; Keshri, A.; O'Sullivan, B.; Taniere, P.; Ghafoor, Q.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erlotinib versus docetaxel as second-lin

✍ Garassino, Marina Chiara; Martelli, Olga; Broggini, Massimo; Farina, Gabriella; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 279 KB

The relevance of stable disease (SD) as

✍ Grossi, F.; Sini, C.; Barletta, G.; Rijavec, E.; Genova, C.; Dal Bello, G.; Pron 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 63 KB

PCN36 ECONOMIC EVALUATION OF ERLOTINIB,

✍ S Capri; A Morabito; G Carillio; F Grossi; R Longo; G Cerea; F Rossetti 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Activity and safety of erlotinib as seco

✍ David Rossi; Donatella Dennetta; Marcello Ugolini; Vincenzo Catalano; Paolo Ales 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 129 KB

A phase II study of docetaxel (D) and ge

✍ Agelaki, S.; Papadakis, E.; Tsiafaki, X.; Rapti, A.; Toubis, M.; Bania, E.; Kalb 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 158 KB

P-542 Carboplatin (C) and docetaxel (D)

✍ Numico, G.; Buffoni, L.; Dongiovanni, V.; Schena, M.; Fissore, C.; Fea, E.; Occe 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 175 KB